BioPharmSignal logoBioPharmSignal

Biotech News

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Sight Sciences (SGHT)Sight Sciences2026-06-25 13:46 ESTClinical readout

Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc.

Open original release

Related news

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

SGHTSight Sciences2026-06-25 13:46 EST

New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences Announces the Release of its Sustainability Report

SGHTSight Sciences2026-06-25 13:46 EST

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

View all latest news

Sight Sciences

Sight Sciences is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

SGHTZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

SGHTZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

SGHTBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

SGHTGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

SGHTMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
5.34 USD
Market cap
289.46M USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States